ES2343403T3 - Derivados fosfolipidos de acido valproico y sus mezclas. - Google Patents

Derivados fosfolipidos de acido valproico y sus mezclas. Download PDF

Info

Publication number
ES2343403T3
ES2343403T3 ES01949851T ES01949851T ES2343403T3 ES 2343403 T3 ES2343403 T3 ES 2343403T3 ES 01949851 T ES01949851 T ES 01949851T ES 01949851 T ES01949851 T ES 01949851T ES 2343403 T3 ES2343403 T3 ES 2343403T3
Authority
ES
Spain
Prior art keywords
vpa
pharmaceutical composition
glycerol
composition according
phosphocholine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES01949851T
Other languages
English (en)
Spanish (es)
Inventor
Alexander Kozak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DPHARM Ltd
D Pharm Ltd
Original Assignee
DPHARM Ltd
D Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DPHARM Ltd, D Pharm Ltd filed Critical DPHARM Ltd
Application granted granted Critical
Publication of ES2343403T3 publication Critical patent/ES2343403T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fats And Perfumes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
ES01949851T 2000-07-12 2001-07-10 Derivados fosfolipidos de acido valproico y sus mezclas. Expired - Lifetime ES2343403T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/614,271 US6313106B1 (en) 1995-06-07 2000-07-12 Phospholipid derivatives of valproic acid and mixtures thereof
US614271 2000-07-12

Publications (1)

Publication Number Publication Date
ES2343403T3 true ES2343403T3 (es) 2010-07-30

Family

ID=24460534

Family Applications (1)

Application Number Title Priority Date Filing Date
ES01949851T Expired - Lifetime ES2343403T3 (es) 2000-07-12 2001-07-10 Derivados fosfolipidos de acido valproico y sus mezclas.

Country Status (20)

Country Link
US (2) US6313106B1 (https=)
EP (1) EP1315506B1 (https=)
JP (1) JP5140224B2 (https=)
KR (1) KR100801213B1 (https=)
CN (1) CN100536851C (https=)
AT (1) ATE461697T1 (https=)
AU (2) AU7096201A (https=)
BR (1) BR0112337A (https=)
CA (1) CA2415354C (https=)
CY (1) CY1110113T1 (https=)
CZ (1) CZ305745B6 (https=)
DE (1) DE60141636D1 (https=)
DK (1) DK1315506T3 (https=)
ES (1) ES2343403T3 (https=)
HU (1) HU229320B1 (https=)
IL (1) IL153147A0 (https=)
MX (1) MXPA03000326A (https=)
NZ (1) NZ522788A (https=)
PT (1) PT1315506E (https=)
WO (1) WO2002007669A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6313106B1 (en) * 1995-06-07 2001-11-06 D-Pharm Ltd. Phospholipid derivatives of valproic acid and mixtures thereof
US6518311B2 (en) * 1997-07-09 2003-02-11 D-Pharm Ltd. Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
US7582678B2 (en) 1997-07-09 2009-09-01 D-Pharm Limited Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
CN1649600A (zh) 2002-02-28 2005-08-03 A&D生物科学公司 氟西汀及类似物的糖醛酰胺、苷和原酸酯苷及其应用
WO2003079980A2 (en) * 2002-03-19 2003-10-02 A & D Bioscience, Inc. Caboxylic acid glycuronides, glycosamides and glycosides of quinolones, penicillins, analogs, and uses thereof
WO2003086475A1 (en) * 2002-04-12 2003-10-23 A & D Bioscience, Inc. Conjugates comprising cancer cell specific ligands, a sugar and diagnostic agents, and uses thereof
CA2484891A1 (en) * 2002-05-07 2003-11-20 A & D Bioscience, Inc. Conjugates comprising central nervous system active drug
US20050215487A1 (en) * 2002-06-27 2005-09-29 Holick Michael F Conjugates comprising an nsaid and a sugar and uses thereof
US20050170063A1 (en) * 2004-01-29 2005-08-04 Lalit Chordia Production of powder and viscous material
GB2460976B (en) * 2005-03-24 2010-02-17 John Marcell Davis Methods of determining compounds useful in the treatment of bipolar disorder and methods of treating such disorders
WO2007028030A2 (en) * 2005-09-02 2007-03-08 Picobella, Llc Oncogenic regulatory rnas for diagnostics and therapeutics
US7459280B2 (en) * 2006-02-27 2008-12-02 Picobella, Llc Methods for diagnosing and treating kidney cancer
US20080267977A1 (en) * 2007-04-26 2008-10-30 Friedrich-Alexander University Of Erlangen-Nuremberg Combined immunological agent and sensitizing agent for the treatment of cancer
KR200451744Y1 (ko) * 2008-10-10 2011-01-10 이종희 휴대용 운동기구
JP2015533114A (ja) * 2012-05-08 2015-11-19 セリックスビオ プライヴェート リミテッド 神経疾患の治療のための組成物及び方法
CN104230981B (zh) * 2013-06-20 2016-05-18 江苏恩华药业股份有限公司 丙戊酸磷脂衍生物的制备方法
PT3429580T (pt) * 2016-03-16 2025-08-12 Buzzelet Development And Technologies Ltd Composição de canabinoides enriquecida em terpenos
CN108659038B (zh) * 2017-03-31 2022-01-11 江苏恩华药业股份有限公司 1-硬脂酰-2-丙戊酰-sn-甘油-3-磷脂酰胆碱的多晶型物及制备方法
CN108659037B (zh) * 2017-03-31 2022-01-11 江苏恩华药业股份有限公司 丙戊酸磷脂衍生物的多晶型物及制备方法
KR101864085B1 (ko) * 2017-09-22 2018-06-01 동아대학교 산학협력단 발프로산 유도체, 이의 제조방법 및 이를 포함하는 항경련제
CN110407867A (zh) * 2018-04-28 2019-11-05 江苏恩华药业股份有限公司 丙戊酸磷脂衍生物的新晶型及其制备方法
CN114344303B (zh) * 2022-01-13 2023-05-09 江苏海洋大学 一种新型精神药物固体分散体及制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4654370A (en) * 1979-03-12 1987-03-31 Abbott Laboratories Glyceryl valproates
US4988731A (en) 1979-08-20 1991-01-29 Abbott Laboratories Sodium hydrogen divalproate oligomer
US5212326A (en) 1979-08-20 1993-05-18 Abbott Laboratories Sodium hydrogen divalproate oligomer
US4558070A (en) 1983-10-26 1985-12-10 Abbott Laboratories Acid salts of valproic acid
CA1260393A (en) * 1984-10-16 1989-09-26 Lajos Tarcsay Liposomes of synthetic lipids
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
IT1201149B (it) 1987-01-14 1989-01-27 Indena Spa Complessi di bioflavonoidi con fosfolipidi,loro preparazione,uso e composizioni farmaceutici e cosmetiche
ATE151467T1 (de) 1987-11-30 1997-04-15 Univ Iowa Res Found Durch modifikationen an der 3'-terminalen phosphodiesterbindung stabilisierte dna moleküle, ihre verwendung als nukleinsäuresonden sowie als therapeutische mittel zur hemmung der expression spezifischer zielgene
DE3801587A1 (de) 1988-01-21 1989-08-03 Hoechst Ag Neue aminosaeureglyceride, verfahren zu ihrer herstellung, sie enthaltende arzneimittel und deren verwendung
CA2049028A1 (en) 1989-03-07 1990-09-08 Genentech, Inc. Covalent conjugates of lipid and oligonucleotide
JPH03133987A (ja) 1989-10-18 1991-06-07 Kowa Yakuhin Kogyo Kk ２‐マイトマイシンｃ‐スクシニル‐１，３‐ジパルミトイルグリセロールおよびその製造法
WO1991016920A1 (en) 1990-05-07 1991-11-14 Vical, Inc. Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
CH679856A5 (https=) 1990-07-04 1992-04-30 Lonza Ag
US5149794A (en) 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
AU668873B2 (en) 1991-07-12 1996-05-23 Chimerix, Inc. Antiviral liponucleosides: treatment of hepatitis B
US6015834A (en) 1992-10-20 2000-01-18 Toronto Neuroprotection Group In vivo treatment of mammalian cells with a cell membrane permeant calcium buffer
IL105244A (en) 1993-03-31 2003-07-31 Dpharm Ltd Prodrugs with enhanced penetration into cells
US6413949B1 (en) 1995-06-07 2002-07-02 D-Pharm, Ltd. Prodrugs with enhanced penetration into cells
US6313106B1 (en) * 1995-06-07 2001-11-06 D-Pharm Ltd. Phospholipid derivatives of valproic acid and mixtures thereof
IL121268A0 (en) * 1997-07-09 1998-01-04 Dpharm Ltd Branched chain fatty acids their derivatives and use in the treatment of central nervous system disorders
KR100301803B1 (ko) 1998-06-05 2001-09-22 김영환 박막트랜지스터 및 그의 제조방법

Also Published As

Publication number Publication date
DE60141636D1 (de) 2010-05-06
IL153147A0 (en) 2003-06-24
CA2415354A1 (en) 2002-01-31
PT1315506E (pt) 2010-05-17
AU2001270962B2 (en) 2006-03-16
DK1315506T3 (da) 2010-05-31
HUP0302635A2 (hu) 2003-11-28
BR0112337A (pt) 2004-06-08
US6313106B1 (en) 2001-11-06
JP2004509854A (ja) 2004-04-02
JP5140224B2 (ja) 2013-02-06
EP1315506A2 (en) 2003-06-04
AU7096201A (en) 2002-02-05
KR100801213B1 (ko) 2008-02-05
CN1774252A (zh) 2006-05-17
KR20030034099A (ko) 2003-05-01
CA2415354C (en) 2009-09-29
AU2001270962B8 (en) 2006-08-10
HUP0302635A3 (en) 2007-06-28
ATE461697T1 (de) 2010-04-15
WO2002007669A3 (en) 2003-01-09
NZ522788A (en) 2005-04-29
MXPA03000326A (es) 2004-12-13
WO2002007669A2 (en) 2002-01-31
EP1315506B1 (en) 2010-03-24
CN100536851C (zh) 2009-09-09
CZ305745B6 (cs) 2016-03-02
US20040033987A1 (en) 2004-02-19
CZ200386A3 (cs) 2003-06-18
EP1315506A4 (en) 2005-03-30
CY1110113T1 (el) 2015-01-14
HU229320B1 (en) 2013-10-28

Similar Documents

Publication Publication Date Title
ES2343403T3 (es) Derivados fosfolipidos de acido valproico y sus mezclas.
AU2001270962A1 (en) Phospholipid derivatives of valproic acid and mixtures thereof
CN102421438B (zh) 乙酰水杨酸和茶氨酸的水溶性共结晶体的静脉制剂
CN101506143B (zh) 具有快速皮肤穿透速度的带正电荷的水溶性的对乙酰氨基酚及其相关化合物的前药
ES2244098T3 (es) Un conjugado covalente de clozapina con un acido graso y su uso para tratar la esquizofrenia.
ES2214729T3 (es) Acido 9-cis-retinoico para enfermedades inmunes inducidas por celulas.
ES2540551T3 (es) Antagonistas de receptores opioides periféricos y usos de los mismos
ES2472545T3 (es) Profármacos de diclofenaco solubles en agua con carga positiva y con una tasa de penetración en piel muy rápida
ES2316489T3 (es) Composiciones farmaceuticas de fenretinida que tienen biodisponibilidad aumentada y metodos de uso de las mismas.
WO2009114368A2 (en) Activated nitric oxide donors and methods of making and using thereof
ES2827796T3 (es) Composiciones y procedimientos relativos a sales de mediadores pro-resolutivos especializados de inflamación
CN113853368A (zh) 由支架部分制备的脂质缀合物
ES2590708T3 (es) Método para preparar ésteres grasos de creatina, ésteres grasos de creatina preparados de este modo y usos de los mismos
Kurz et al. Drug–phospholipid conjugates as potential prodrugs: synthesis, characterization, and degradation by pancreatic phospholipase A2
ES2884123T3 (es) Formulaciones de inhibidores de xantina oxidasa
AU778340B2 (en) Therapeutic compositions containing glutathione analogs
IL153147A (en) Pharmaceutical compositions comprising phospholipid conjugates of valproic acid or derivatives thereof
ES2369365T3 (es) Composiciones formadoras de partículas que contienen pirrolocarbazoles fusionados.
ITMI20001741A1 (it) Composizioni farmaceutiche comprendenti agenti antiinfiammatori e loro usi
Reddy et al. Lipid-based anticancer prodrugs
HK40059576A (en) Lipid conjugate prepared from scaffold moiety
CN103351308A (zh) 具有快速皮肤穿透速度的带正电荷的水溶性的对乙酰氨基酚及其相关化合物的前药
HK1137414A (en) Positively charged water-soluble prodrugs of acetaminophen and related compounds with very fast skin penetration rate
HK1190388A (en) Positively charged water-soluble prodrugs of acetaminophen and related compounds with very fast skin penetration rate